COVID-19重症患者谵妄的患病率及危险因素(COVID-D):一项多中心队列研究
该多中心队列研究纳入14个国家69个ICU的2088例COVID-19成年患者,旨在调查谵妄和昏迷的患病率及谵妄的危险因素。结果显示,81.6%的患者出现昏迷(中位10.0天),54.9%出现谵妄(中位3.0天);机械通气、约束、苯二氮䓬类、阿片类、血管升压药及抗精神病药使用均与次日谵妄风险升高相关(p≤0.04),而家属探视(当面或虚拟)与谵妄风险降低相关(p<0.0001)。作者认为苯二氮䓬类使用和缺乏家属探视是可干预的危险因素,为减少COVID-19患者的急性脑功能障碍提供了机会。
要点
- COVID-19重症患者中81.6%出现昏迷(中位10.0天),54.9%出现谵妄(中位3.0天),急性脑功能障碍高发且持续时间长。
- 机械通气、约束、苯二氮䓬类、阿片类、血管升压药及抗精神病药使用均与次日谵妄风险升高独立相关(均p≤0.04)。
- 家属探视(当面或虚拟)与次日谵妄风险降低相关(p<0.0001)。
- 21天研究期间,患者无谵妄或无昏迷的存活天数中位仅5.0天(IQR 0.0-14.0)。
- 基线年龄较大、SAPS II较高、男性、吸烟或酗酒、第1天使用血管升压药及第1天有创机械通气均与无谵妄无昏迷存活天数减少独立相关(均p<0.01)。
适用人群与场景
- 2020年4月28日前入住参与ICU的≥18岁SARS-CoV-2感染患者。
- 排除:濒死或入ICU 24小时内撤除生命支持者、囚犯、既往精神疾病、神经退行性疾病、先天性或获得性脑损伤、肝性昏迷、药物过量、自杀未遂、盲或聋患者。
研究设计与关键结果
- 多中心队列研究,纳入14个国家69个ICU的2088例COVID-19成年患者;中位年龄64岁(IQR 54-71),中位SAPS II 40.0(30.0-53.0)。
- 1397/2088(66.9%)入ICU当天接受有创机械通气,1827/2088(87.5%)住院期间某时点接受有创机械通气。
- 1337/2088(64.0%)使用苯二氮䓬类(中位7.0天,IQR 4.0-12.0),1481/2088(70.9%)使用丙泊酚(中位7.0天,IQR 4.0-11.0);有创机械通气期间中位RASS评分为-4(-5至-3)。
- 1704/2088(81.6%)出现昏迷(中位10.0天,IQR 6.0-15.0),1147/2088(54.9%)出现谵妄(中位3.0天,IQR 2.0-6.0)。
- 机械通气、约束、苯二氮䓬类、阿片类、血管升压药及抗精神病药使用均与次日谵妄风险升高相关(均p≤0.04);家属探视(当面或虚拟)与谵妄风险降低相关(p<0.0001)。
- 21天研究期间,无谵妄或无昏迷的存活天数中位5.0天(IQR 0.0-14.0)。
- 基线年龄较大、SAPS II较高、男性、吸烟或酗酒、第1天使用血管升压药及第1天有创机械通气均与无谵妄无昏迷存活天数减少独立相关(均p<0.01)。
- 601/2088(28.8%)在入住28天内死亡,大多数死亡发生在ICU。
证据类型、等级与局限
- 证据类型:多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为苯二氮䓬类使用和缺乏家属探视是可干预的谵妄危险因素,这些数据为减少COVID-19患者的急性脑功能障碍提供了机会。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: To date, 750 000 patients with COVID-19 worldwide have required mechanical ventilation and thus are at high risk of acute brain dysfunction (coma and delirium). We aimed to investigate the prevalence of delirium and coma, and risk factors for delirium in critically ill patients with COVID-19, to aid the development of strategies to mitigate delirium and associated sequelae.
METHODS: This multicentre cohort study included 69 adult intensive care units (ICUs), across 14 countries. We included all patients (aged ≥18 years) admitted to participating ICUs with severe acute respiratory syndrome coronavirus 2 infection before April 28, 2020. Patients who were moribund or had life-support measures withdrawn within 24 h of ICU admission, prisoners, patients with pre-existing mental illness, neurodegenerative disorders, congenital or acquired brain damage, hepatic coma, drug overdose, suicide attempt, or those who were blind or deaf were excluded. We collected de-identified data from electronic health records on patient demographics, delirium and coma assessments, and management strategies for a 21-day period. Additional data on ventilator support, ICU length of stay, and vital status was collected for a 28-day period. The primary outcome was to determine the prevalence of delirium and coma and to investigate any associated risk factors associated with development of delirium the next day. We also investigated predictors of number of days alive without delirium or coma. These outcomes were investigated using multivariable regression.
FINDINGS: Between Jan 20 and April 28, 2020, 4530 patients with COVID-19 were admitted to 69 ICUs, of whom 2088 patients were included in the study cohort. The median age of patients was 64 years (IQR 54 to 71) with a median Simplified Acute Physiology Score (SAPS) II of 40·0 (30·0 to 53·0). 1397 (66·9%) of 2088 patients were invasively mechanically ventilated on the day of ICU admission and 1827 (87·5%) were invasively mechanical ventilated at some point during hospitalisation. Infusion with sedatives while on mechanical ventilation was common: 1337 (64·0%) of 2088 patients were given benzodiazepines for a median of 7·0 days (4·0 to 12·0) and 1481 (70·9%) were given propofol for a median of 7·0 days (4·0 to 11·0). Median Richmond Agitation-Sedation Scale score while on invasive mechanical ventilation was -4 (-5 to -3). 1704 (81·6%) of 2088 patients were comatose for a median of 10·0 days (6·0 to 15·0) and 1147 (54·9%) were delirious for a median of 3·0 days (2·0 to 6·0). Mechanical ventilation, use of restraints, and benzodiazepine, opioid, and vasopressor infusions, and antipsychotics were each associated with a higher risk of delirium the next day (all p≤0·04), whereas family visitation (in person or virtual) was associated with a lower risk of delirium (p<0·0001). During the 21-day study period, patients were alive without delirium or coma for a median of 5·0 days (0·0 to 14·0). At baseline, older age, higher SAPS II scores, male sex, smoking or alcohol abuse, use of vasopressors on day 1, and invasive mechanical ventilation on day 1 were independently associated with fewer days alive and free of delirium and coma (all p<0·01). 601 (28·8%) of 2088 patients died within 28 days of admission, with most of those deaths occurring in the ICU.
INTERPRETATION: Acute brain dysfunction was highly prevalent and prolonged in critically ill patients with COVID-19. Benzodiazepine use and lack of family visitation were identified as modifiable risk factors for delirium, and thus these data present an opportunity to reduce acute brain dysfunction in patients with COVID-19.
TRANSLATIONS: For the French and Spanish translations of the abstract see Supplementary Materials section.
参考来源
- Pun BT, Badenes R, Heras La Calle G, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. 2021. PMID: 33428871. doi:10.1016/S2213-2600(20)30552-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。